Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits.

O'Gorman CS, O'Neill MB, Conwell LS.

Vasc Health Risk Manag. 2010 Dec 20;7:1-14. doi: 10.2147/VHRM.S7356. Review.

PMID:
21339908
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Kones R.

Drug Des Devel Ther. 2011;5:325-80. doi: 10.2147/DDDT.S14934. Epub 2011 Jun 13. Review.

PMID:
21792295
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Lipid-lowering therapy: who can benefit?

Lewis SJ.

Vasc Health Risk Manag. 2011;7:525-34. doi: 10.2147/VHRM.S23113. Epub 2011 Aug 24. Review.

PMID:
21915170
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Management of dyslipidemias in the age of statins.

Green ML.

Prim Care. 2003 Dec;30(4):641-69. Review.

PMID:
15024890
[PubMed - indexed for MEDLINE]
5.

Cholesterol and triglyceride management: "if I take my medication, can I eat what I want?".

Braun LT.

J Cardiovasc Nurs. 2010 May-Jun;25(3):241-6. doi: 10.1097/JCN.0b013e3181cec6d1.

PMID:
20386249
[PubMed - indexed for MEDLINE]
6.

Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.

Wierzbicki AS, Viljoen A.

Drug Saf. 2010 Feb 1;33(2):115-25. doi: 10.2165/11319490-000000000-00000. Review.

PMID:
20082538
[PubMed - indexed for MEDLINE]
7.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
[PubMed - indexed for MEDLINE]
8.

Screening for Lipid Disorders in Children and Adolescents [Internet].

Haney EM, Huffman LH, Bougatsos C, Freeman M, Fu R, Steiner RD, Helfand M, Nelson HD.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Jul.

9.

Screening and Interventions for Childhood Overweight [Internet].

Whitlock EP, Williams SB, Gold R, Smith P, Shipman S.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Jul.

10.

Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

Kones R.

Drug Des Devel Ther. 2010 Dec 9;4:383-413. doi: 10.2147/DDDT.S10812. Review.

PMID:
21267417
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.

Breuer HW.

Curr Med Res Opin. 2001;17(1):60-73. Review.

PMID:
11464448
[PubMed - indexed for MEDLINE]
12.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

PMID:
17408535
[PubMed - indexed for MEDLINE]
Free Article
13.

Optimal medical management of peripheral arterial disease.

Rice TW, Lumsden AB.

Vasc Endovascular Surg. 2006 Aug-Sep;40(4):312-27. Review.

PMID:
16959725
[PubMed - indexed for MEDLINE]
14.

Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.

Duplaga BA.

Ann Pharmacother. 1999 Nov;33(11):1224-7. Review.

PMID:
10573325
[PubMed - indexed for MEDLINE]
15.

Youth resistance training: updated position statement paper from the national strength and conditioning association.

Faigenbaum AD, Kraemer WJ, Blimkie CJ, Jeffreys I, Micheli LJ, Nitka M, Rowland TW.

J Strength Cond Res. 2009 Aug;23(5 Suppl):S60-79. doi: 10.1519/JSC.0b013e31819df407. Review.

PMID:
19620931
[PubMed - indexed for MEDLINE]
16.

HDL-C: role as a risk modifier.

Barter P.

Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Review.

PMID:
22152280
[PubMed - indexed for MEDLINE]
17.

The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.

Prescott WA Jr, Streetman DA, Streetman DS.

Ann Pharmacother. 2004 Dec;38(12):2105-14. Epub 2004 Oct 26. Review.

PMID:
15507504
[PubMed - indexed for MEDLINE]
18.

Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.

McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing.

Circulation. 2007 Apr 10;115(14):1948-67. Epub 2007 Mar 21.

PMID:
17377073
[PubMed - indexed for MEDLINE]
Free Article
19.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
[PubMed - indexed for MEDLINE]
20.

Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.

Pedersen TR.

Am J Cardiovasc Drugs. 2010;10 Suppl 1:10-7. doi: 10.2165/1158822-S0-000000000-00000. Review.

PMID:
21391729
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk